Toward Catalytic Antibiotics: Redesign of Fluoroquinolones to Catalytically Fragment Chromosomal DNA.

Anti-Bacterial Agents / pharmacology DNA DNA Gyrase Fluoroquinolones / pharmacology Topoisomerase II Inhibitors / pharmacology
DNA cleavage antimicrobial resistance catalytic antibiotic cyclen fluoroquinolone metallodrugs

Journal

ACS infectious diseases
ISSN: 2373-8227
Titre abrégé: ACS Infect Dis
Pays: United States
ID NLM: 101654580

Informations de publication

Date de publication:
12 03 2021
Historique:
pubmed: 16 1 2021
medline: 24 6 2021
entrez: 15 1 2021
Statut: ppublish

Résumé

A library of ciprofloxacin-nuclease conjugates was designed and synthesized to investigate their potential as catalytic antibiotics. The Cu(II) complexes of the new designer compounds (i) showed excellent

Identifiants

DOI: 10.1021/acsinfecdis.0c00777 PMID: 33448785
pubmed: 33448785
doi: 10.1021/acsinfecdis.0c00777
doi:

Substances chimiques

Anti-Bacterial Agents 0
Fluoroquinolones 0
Topoisomerase II Inhibitors 0
DNA 9007-49-2
DNA Gyrase EC 5.99.1.3

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

608-623

Auteurs

Moshe N Goldmeier (MN)

Edith and Joseph Fischer Enzyme Inhibitors Laboratory, Schulich Faculty of Chemistry, Technion - Israel Institute of Technology, Haifa 3200003, Israel.

Sofya Katz (S)

Edith and Joseph Fischer Enzyme Inhibitors Laboratory, Schulich Faculty of Chemistry, Technion - Israel Institute of Technology, Haifa 3200003, Israel.

Fabian Glaser (F)

The Lorry I. Lokey Interdisciplinary Center for Life Sciences and Engineering, Technion - Israel Institute of Technology, Haifa 3200003, Israel.

Valery Belakhov (V)

Edith and Joseph Fischer Enzyme Inhibitors Laboratory, Schulich Faculty of Chemistry, Technion - Israel Institute of Technology, Haifa 3200003, Israel.

Alina Khononov (A)

Edith and Joseph Fischer Enzyme Inhibitors Laboratory, Schulich Faculty of Chemistry, Technion - Israel Institute of Technology, Haifa 3200003, Israel.

Timor Baasov (T)

Edith and Joseph Fischer Enzyme Inhibitors Laboratory, Schulich Faculty of Chemistry, Technion - Israel Institute of Technology, Haifa 3200003, Israel.
ORCID: 0000-0002-1427-2619

Articles similaires

Vancomycin-associated DRESS demonstrates delay in AST abnormalities.

Ahmed Hussein, Kateri L Schoettinger, Jourdan Hydol-Smith et al.
1.00
Humans Drug Hypersensitivity Syndrome Vancomycin Female Male

Management of the infected total elbow arthroplasty.

Joaquin Sanchez-Sotelo
1.00
Humans Arthroplasty, Replacement, Elbow Prosthesis-Related Infections Debridement Anti-Bacterial Agents

Mathematical modeling of vancomycin release from Poly-L-Lactic Acid-Coated implants.

Papon Thamvasupong, Kwanchanok Viravaidya-Pasuwat
1.00
Vancomycin Polyesters Anti-Bacterial Agents Models, Theoretical Drug Liberation

Effectiveness of bundled care in the management of cerebral hemorrhage complicated by pulmonary infection in China: A systematic review and meta-analysis.

Yamei Zhang, Xiulan Wu, Ming Lu et al.
1.00
Humans China Cerebral Hemorrhage Patient Care Bundles Length of Stay

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antibactériens › Toward Catalytic Antibiotics: Redesign of...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Acides nucléiques › ADN › Toward Catalytic Antibiotics: Redesign of...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines bactériennes › DNA gyrase › Toward Catalytic Antibiotics: Redesign of...
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › Quinoléines › Quinolinone › Fluoroquinolones › Toward Catalytic Antibiotics: Redesign of...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Inhibiteurs des topoisomérases › Inhibiteurs de la topoisomérase-II › Toward Catalytic Antibiotics: Redesign of...